

*** NOTICES ***

JPO and INPIT are not responsible for any damages caused by the use of this translation.

- 1.This document has been translated by computer. So the translation may not reflect the original precisely.
- 2.**** shows the word which can not be translated.
- 3.In the drawings, any words are not translated.

WRITTEN AMENDMENT

[Written amendment]

[Filing date]November 10, Heisei 4

[Amendment 1]

[Document to be Amended]Specification

[Item(s) to be Amended]0023

[Method of Amendment]Change

[Proposed Amendment]

[0023]for the involution osteoporosis patient, high grade EPA-E pharmaceutical preparation (Epadel (trademark): -- Mochida Pharmaceutical 6 capsule (1800 mg as EPA-E)/-- Japanese) was divided into 2 thru/or 3 times, and was prescribed for the patient for three to six months in taking orally. The spinal column bone density patient's administration before and after administration was measured, and the rate of change was compared with the thing of the control group (EPA-E un-prescribing a medicine for the patient). If in charge of measurement of bone density, the average bone density ($L2-L4BMD (g/cm^2)$) from second lumbar vertebra to fourth lumbar vertebra was measured by dual-energy x-ray absorptiometry (DPXA) using DPX (made by LUNER).

[Amendment 2]

[Document to be Amended]Specification

[Item(s) to be Amended]0025

[Method of Amendment]Change

[Proposed Amendment]

[0025]

第 3 表

$L_3 - L_4$ BMD

	<u>投与前(g/cm²)</u>	<u>投与後(g/cm²)</u>	変化率(%)
EPA-E投与群	0.862 ± 0.024	0.879 ± 0.026	1.90±0.0
コントロール群	0.995 ± 0.094	0.977 ± 0.095	-2.11±0.0

The change in BMD of the vertebra measured by this method is often reflecting the change in the cancellous bone in the vertebra.

It is an index with which progress of osteoporosis is expressed well.

[Translation done.]